Erkki Ruoslahti

Summary

Publications

  1. pmc Peptides as targeting elements and tissue penetration devices for nanoparticles
    Erkki Ruoslahti
    Center for Nanomedicine, UCSB, Biology II Bldg, University of California, Santa Barbara, CA 93106 9610, USA
    Adv Mater 24:3747-56. 2012
  2. pmc Application of a proapoptotic peptide to intratumorally spreading cancer therapy
    Renwei Chen
    Center for Nanomedicine, Sanford Burnham Medical Research Institute, University of California, Santa Barbara, CA, USA
    Cancer Res 73:1352-61. 2013
  3. pmc Nanoparticle-induced vascular blockade in human prostate cancer
    Lilach Agemy
    Vascular Mapping Laboratory, Center for Nanomedicine, Sanford Burnham Medical Research Institute at the University of California at Santa Barbara UCSB, Santa Barbara, CA, USA
    Blood 116:2847-56. 2010
  4. pmc Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs
    Kazuki N Sugahara
    Vascular Mapping Laboratory, Center for Nanomedicine, Sanford Burnham Medical Research Institute at University of California at Santa Barbara, Biology II Building, University of California, Santa Barbara, CA 93106 9610, USA
    Science 328:1031-5. 2010
  5. pmc Tissue-penetrating delivery of compounds and nanoparticles into tumors
    Kazuki N Sugahara
    Vascular Mapping Center, Burnham Institute for Medical Research at UCSB, Biology II Building, University of California, Santa Barbara, Santa Barbara, CA 93106 9610, USA
    Cancer Cell 16:510-20. 2009
  6. pmc Cooperative nanomaterial system to sensitize, target, and treat tumors
    Ji Ho Park
    Materials Science and Engineering Program, University of California, San Diego, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 107:981-6. 2010
  7. pmc Magnetic luminescent porous silicon microparticles for localized delivery of molecular drug payloads
    Luo Gu
    Department of Chemistry and Biochemistry, Materials Science and Engineering Program, University of California, San Diego, 9500 Gilman, La Jolla, CA 92093, USA
    Small 6:2546-52. 2010
  8. pmc TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells
    Chris Brunquell
    Center for Nanomedicine, Sanford Burnham Medical Research Institute, Santa Barbara, California, USA
    Mol Cancer Res 10:1482-95. 2012
  9. pmc Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma
    Lilach Agemy
    Center for Nanomedicine, Sanford Burnham Medical Research Institute, University of California, Santa Barbara, CA 93106 9610, USA
    Proc Natl Acad Sci U S A 108:17450-5. 2011
  10. doi Mapping of vascular ZIP codes by phage display
    Tambet Teesalu
    Center for Nanomedicine, Sanford Burnham Medical Research Institute at UCSB, Santa Barbara, California, USA
    Methods Enzymol 503:35-56. 2012

Collaborators

  • Tambet Teesalu
  • Michael J Sailor
  • Hector Biliran
  • Lise Roth
  • Ruth Nussinov
  • Yi Xiao
  • Douglas Hanahan
  • Shiladitya Sengupta
  • BALABHASKAR PRABHAKARPANDIAN
  • Katherine W Ferrara
  • Yuko Kono
  • David Zanuy
  • Dimitris Missirlis
  • Jai W Seo
  • Lilach Agemy
  • Kazuki N Sugahara
  • Venkata Ramana Kotamraju
  • Ji Ho Park
  • Poornima Kolhar
  • Priya Prakash Karmali
  • Renwei Chen
  • Juliana Hamzah
  • Olivier M Girard
  • Robert F Mattrey
  • Luo Gu
  • Sajid Hussain
  • Gary B Braun
  • Ashish A Kulkarni
  • Oran Erster
  • Chris Brunquell
  • Venkata R Kotamraju
  • Dinorah Friedmann-Morvinski
  • Jinpeng Wang
  • Valentina Fogal
  • Tero A H Järvinen
  • Sangeeta N Bhatia
  • Geoffrey von Maltzahn
  • Maria Rodriguez-Fernandez
  • Francis J Doyle
  • Daniela M Dinulescu
  • Kapil Pant
  • Sudipta Basu
  • Madhumitha Ramachandran
  • Aaron C Anselmo
  • Bhaskar Roy
  • Gregory A Wyant
  • Raghunath A Mashelkar
  • Xiuquan Luo
  • Poornima S Rao
  • Poulomi Sengupta
  • Shweta Sharma
  • Samir Mitragotri
  • Aaron Goldman
  • Ayaat Mahmoud
  • Vivek Gupta
  • Abeer M Jabaiah
  • Tobias D Schoep
  • Sejal S Hall
  • Jennifer A Getz
  • SHUBHA KALE IRELAND
  • Patrick S Daugherty
  • Scott Jennings
  • Jerry M Thomas
  • M Karen J Gagnon
  • David Peters
  • Qiang Gong
  • Yanli Liu
  • Lisa M Mahakian
  • Seung Soo Oh
  • Inder M Verma
  • Jonathan D Adams
  • Minseon Cho
  • Venkata Ramana Kotamrajua
  • Brian S Ferguson
  • Andrew T Csordas
  • H Tom Soh
  • Carlos Aleman
  • Francisco J Sayago
  • Sherry T Hikita
  • Daniel R Greenwald
  • Kunal Gujraty
  • Ana I Jimenez
  • Dennis O Clegg
  • Carlos Cativiela
  • Mary Jue Xu
  • Kim H Duong
  • Matthew Tirrell
  • Matthew Black
  • Mark Kastantin

Detail Information

Publications25

  1. pmc Peptides as targeting elements and tissue penetration devices for nanoparticles
    Erkki Ruoslahti
    Center for Nanomedicine, UCSB, Biology II Bldg, University of California, Santa Barbara, CA 93106 9610, USA
    Adv Mater 24:3747-56. 2012
    ..This review discusses the recent developments in the nanoparticle targeting field with emphasis on peptides that home to vascular "zip codes" in target tissues and provide a tissue- and cell-penetrating function...
  2. pmc Application of a proapoptotic peptide to intratumorally spreading cancer therapy
    Renwei Chen
    Center for Nanomedicine, Sanford Burnham Medical Research Institute, University of California, Santa Barbara, CA, USA
    Cancer Res 73:1352-61. 2013
    ..Using iRGD to facilitate the spreading of a therapeutic agent throughout the tumor mass may be a useful adjunct to local therapy for tumors that are surgically inoperable or difficult to treat systemically...
  3. pmc Nanoparticle-induced vascular blockade in human prostate cancer
    Lilach Agemy
    Vascular Mapping Laboratory, Center for Nanomedicine, Sanford Burnham Medical Research Institute at the University of California at Santa Barbara UCSB, Santa Barbara, CA, USA
    Blood 116:2847-56. 2010
    ..Treatment of mice with prostate cancer with multiple doses of the nanoworms induced tumor necrosis and a highly significant reduction in tumor growth...
  4. pmc Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs
    Kazuki N Sugahara
    Vascular Mapping Laboratory, Center for Nanomedicine, Sanford Burnham Medical Research Institute at University of California at Santa Barbara, Biology II Building, University of California, Santa Barbara, CA 93106 9610, USA
    Science 328:1031-5. 2010
    ..Thus, coadministration of iRGD may be a valuable way to enhance the efficacy of anticancer drugs while reducing their side effects, a primary goal of cancer therapy research...
  5. pmc Tissue-penetrating delivery of compounds and nanoparticles into tumors
    Kazuki N Sugahara
    Vascular Mapping Center, Burnham Institute for Medical Research at UCSB, Biology II Building, University of California, Santa Barbara, Santa Barbara, CA 93106 9610, USA
    Cancer Cell 16:510-20. 2009
    ..Conjugation to iRGD significantly improved the sensitivity of tumor-imaging agents and enhanced the activity of an antitumor drug...
  6. pmc Cooperative nanomaterial system to sensitize, target, and treat tumors
    Ji Ho Park
    Materials Science and Engineering Program, University of California, San Diego, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 107:981-6. 2010
    ..Mice containing xenografted MDA-MB-435 tumors that are treated with the combined NR/LyP-1LP therapeutic system display significant reductions in tumor volume compared with individual nanoparticles or untargeted cooperative system...
  7. pmc Magnetic luminescent porous silicon microparticles for localized delivery of molecular drug payloads
    Luo Gu
    Department of Chemistry and Biochemistry, Materials Science and Engineering Program, University of California, San Diego, 9500 Gilman, La Jolla, CA 92093, USA
    Small 6:2546-52. 2010
    ....
  8. pmc TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells
    Chris Brunquell
    Center for Nanomedicine, Sanford Burnham Medical Research Institute, Santa Barbara, California, USA
    Mol Cancer Res 10:1482-95. 2012
    ....
  9. pmc Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma
    Lilach Agemy
    Center for Nanomedicine, Sanford Burnham Medical Research Institute, University of California, Santa Barbara, CA 93106 9610, USA
    Proc Natl Acad Sci U S A 108:17450-5. 2011
    ..Coinjecting the nanoparticles with a tumor-penetrating peptide further enhanced the therapeutic effect. Both models used have proven completely resistant to other therapies, suggesting clinical potential of our nanosystem...
  10. doi Mapping of vascular ZIP codes by phage display
    Tambet Teesalu
    Center for Nanomedicine, Sanford Burnham Medical Research Institute at UCSB, Santa Barbara, California, USA
    Methods Enzymol 503:35-56. 2012
    ..We focus on T7 coliphage platform that our lab prefers to use due to its versatility, physical resemblance of phage particles to clinical nanoparticles, and ease of manipulation...
  11. pmc Targeting of drugs and nanoparticles to tumors
    Erkki Ruoslahti
    Vascular Mapping Center, Sanford Burnham Medical Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
    J Cell Biol 188:759-68. 2010
    ..We review the recent advances in this delivery approach with a focus on the use of molecular markers of tumor vasculature as the primary target and nanoparticles as the delivery vehicle...
  12. pmc Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium
    Poornima Kolhar
    Biomolecular Science and Engineering, University of California Santa Barbara, Santa Barbara, CA 93106, USA
    Proc Natl Acad Sci U S A 110:10753-8. 2013
    ....
  13. pmc Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases
    Oran Erster
    Department of Chemical Engineering, University of California, Santa Barbara, CA 93106, USA
    J Control Release 161:804-12. 2012
    ..These results demonstrate that the activity of disease-associated proteases can be exploited to site-specifically target antibody activity in vivo...
  14. pmc C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
    Tambet Teesalu
    Vascular Mapping Center, The Burnham Institute for Medical Research at University of California, Santa Barbara, CA 93106 9610, USA
    Proc Natl Acad Sci U S A 106:16157-62. 2009
    ..The peptides were able to take payloads up to the nanoparticle size scale deep into extravascular tissue. Our observations have implications in drug delivery and penetration of tissue barriers and tumors...
  15. pmc Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice
    Juliana Hamzah
    Vascular Biology Laboratory, Center for Nanomedicine, The Sanford Burnham Medical Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA 93106 9610, USA
    Proc Natl Acad Sci U S A 108:7154-9. 2011
    ..01) or aortas from atherosclerotic ApoE mice injected with [(18)F]FBA-labeled control peptide (0.05% ID/g, P < 0.001). These results indicate that LyP-1 is a promising agent for the targeting of atherosclerotic lesions...
  16. pmc Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32
    Lilach Agemy
    1 Cancer Research Center, Sanford Burnham Medical Research Institute, La Jolla, California, USA 2 Center for Nanomedicine and Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, California, USA
    Mol Ther 21:2195-204. 2013
    ..The specificity of cell surface p32 for tumor-associated cells, its ability to carry payloads to mitochondria, and the efficacy of the system in important types of cancer make the nanosystem a promising candidate for further development...
  17. pmc Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy
    Ashish A Kulkarni
    Authors Affiliations Laboratory for Nanomedicine, Division of Biomedical Engineering, Department of Medicine, Brigham and Women s Hospital Harvard MIT Division of Health Sciences and Technology Indo US Joint Center for Nanobiotechnology, Cambridge Department of Pathology, Brigham and Women s Hospital Harvard Medical School, Boston Dana Farber Cancer Institute, Brookline, Massachusetts Cancer Research Center, Sanford Burnham Medical Research Institute, La Jolla, San Diego Center for Nanomedicine, Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, California Indian Institute for Science Education Research IISER and National Chemical Laboratories, Pune, India
    Cancer Res 73:6987-97. 2013
    ....
  18. doi Synthetic surfaces for human embryonic stem cell culture
    Poornima Kolhar
    Biomolecular Science and Engineering, University of California, Santa Barbara, CA 93106, USA
    J Biotechnol 146:143-6. 2010
    ..We have developed a novel peptide-based surface that uses a high-affinity cyclic RGD peptide for culture of hESCs under chemically defined conditions...
  19. pmc Biodegradable luminescent porous silicon nanoparticles for in vivo applications
    Ji Ho Park
    Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, USA
    Nat Mater 8:331-6. 2009
    ..These results demonstrate a new type of multifunctional nanostructure with a low-toxicity degradation pathway for in vivo applications...
  20. pmc Selection of phage-displayed peptides on live adherent cells in microfluidic channels
    Jinpeng Wang
    Department of Mechanical Engineering, University of California, Santa Barbara, CA 93106, USA
    Proc Natl Acad Sci U S A 108:6909-14. 2011
    ..As such microfluidic systems can be used with a wide range of biocombinatorial libraries and tissue types, we believe that our method represents an effective approach toward efficient biomarker discovery from patient samples...
  21. pmc Targeting of albumin-embedded paclitaxel nanoparticles to tumors
    Priya Prakash Karmali
    Vascular Mapping Center, Burnham Institute for Medical Research at UCSB, University of California, Santa Barbara, California 93106 9610, USA
    Nanomedicine 5:73-82. 2009
    ..These results show that nanoparticles can be effectively targeted into extravascular tumor tissue and that targeting can enhance the activity of a therapeutic nanoparticle...
  22. pmc Quantity and accessibility for specific targeting of receptors in tumours
    Sajid Hussain
    1 Cancer Research Center, Sanford Burnham Medical Research Institute, La Jolla, California 92037, USA 2 Center for Nanomedicine, and Department of Cell, Molecular and Developmental Biology, University of California Santa Barbara, Santa Barbara, CA 93106 9610, USA
    Sci Rep 4:5232. 2014
    ..The mathematical models we describe make it possible to focus on those aspects of the targeting mechanism that are most likely to have a substantial effect on the overall efficacy of the targeting. ..
  23. pmc Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice
    Tero A H Järvinen
    Vascular Mapping Laboratory, Center for Nanomedicine, Sanford Burnham Medical Research Institute, University of California, Santa Barbara, CA 93106, USA
    Proc Natl Acad Sci U S A 107:21671-6. 2010
    ..This approach may help make reducing scar formation by systemic drug delivery a feasible option for surgery and for the treatment of pathological processes in which scar formation is a problem...
  24. pmc Protein kinase D is a positive regulator of Bit1 apoptotic function
    Hector Biliran
    Burnham Institute for Medical Research at the University of California Santa Barbara, University of California, Santa Barbara, California 93106 9610, USA
    J Biol Chem 283:28029-37. 2008
    ..These studies identify the PKD serine/threonine kinase as one of the signaling molecules through which integrin-mediated cell attachment controls Bit1 activity and anoikis...